These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26525013)

  • 1. Current stage in inflammatory bowel disease: What is next?
    Gómez-Gómez GJ; Masedo Á; Yela C; Martínez-Montiel Mdel P; Casís B
    World J Gastroenterol; 2015 Oct; 21(40):11282-303. PubMed ID: 26525013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why innovation in inflammatory bowel disease drug development will impact your practice.
    Sandborn WJ
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):211-3. PubMed ID: 21338946
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.
    Quetglas EG; Mujagic Z; Wigge S; Keszthelyi D; Wachten S; Masclee A; Reinisch W
    World J Gastroenterol; 2015 Nov; 21(44):12519-43. PubMed ID: 26640330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
    Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
    Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the management of inflammatory bowel disease.
    Grimpen F; Pavli P
    Intern Med J; 2010 Apr; 40(4):258-64. PubMed ID: 20059603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons.
    Filimon AM; Negreanu L; Doca M; Ciobanu A; Preda CM; Vinereanu D
    World J Gastroenterol; 2015 Sep; 21(33):9688-92. PubMed ID: 26361415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.
    Van Asseldonk DP; de Boer NK; Peters GJ; Veldkamp AI; Mulder CJ; Van Bodegraven AA
    Curr Drug Metab; 2009 Nov; 10(9):981-97. PubMed ID: 20214590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional drug therapy for inflammatory bowel disease.
    Bryant RV; Brain O; Travis SP
    Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug delivery strategies for targeted treatment of inflammatory bowel disease].
    Lautenschläger C; Schmidt C; Lange K; Stallmach A
    Z Gastroenterol; 2015 Mar; 53(3):226-34. PubMed ID: 25723326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating nutritional immunology into drug development for inflammatory bowel disease.
    Leber A; Hontecillas R; Tubau-Juni N; Bassaganya-Riera J
    Curr Opin Gastroenterol; 2016 Nov; 32(6):443-449. PubMed ID: 27673381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating inflammatory bowel disease research into clinical medicine.
    Neurath MF; Finotto S
    Immunity; 2009 Sep; 31(3):357-61. PubMed ID: 19766078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Subramanian V; Logan RF
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):593-606. PubMed ID: 22122774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease.
    Cangemi G; Barabino A; Barco S; Parodi A; Arrigo S; Melioli G
    Int J Immunopathol Pharmacol; 2012; 25(2):435-44. PubMed ID: 22697075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.